Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]

  • In development
  • GID-TA11583
  • Expected publication date: TBC

30225-Capivasertib-Abiraterone-Acetate-for-Prostate-Cancer-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)